An offer with an earnout asks you to accept part of the sale price only if specified events occur after closing. The attraction is clear: the buyer can pay more if the business performs. The seller’s exposure deserves equal attention. You may no longer control staffing, payer strategy, spending, or the records used to calculate your payment. Evaluating addiction treatment center earnouts starts with one practical question: can you explain exactly how the money becomes payable, and what could prevent you from receiving it?
Write down cash due at closing, any fixed deferred consideration, and the maximum contingent amount as separate figures. Then list the conditions attached to each. An earnout ceiling is a possible payment, not a guaranteed receivable. For example, the Upbound–Bridge IT merger agreement includes distinct provisions for deferred consideration and an earnout. That non-healthcare transaction illustrates the need to inspect the structure; it does not establish customary terms for a treatment center sale.
Start with the letter of intent. If it says only “additional consideration based on performance,” ask for a proposed formula and operating assumptions before you compare the offer with other bids. For broader ownership context, see private equity in addiction treatment. The specific earnout terms still need their own review, regardless of the buyer’s category.
A metric name is only the starting point. “Revenue,” “collections,” and “EBITDA” can lead to very different payments even when the underlying treatment business is unchanged. Ask the buyer for a worked example using your historical records and the exact proposed definitions. Then identify which judgments the buyer can change during the measurement period. Four questions help expose ambiguity early:
In healthcare, gross billed charges and expected payment can differ substantially. Ardent Health’s accounting disclosure describes contractual adjustments and collection estimates that affect reported revenue. For a treatment center earnout, reconcile the proposed measure to the ledger and payer remittances. If it uses cash collections, determine whether it includes preclosing receivables the buyer already purchased. If it uses net revenue, explain how later refunds and estimate changes affect the result.
Read the payment formula together with the operating covenants, reporting provisions, employment agreement, and dispute procedure. A formula can look reasonable in isolation while another provision makes it difficult to achieve or verify. Use the following six areas to organize a discussion with your financial and legal advisers. The goal is a coherent arrangement that both sides can administer after the transaction team moves on.
Ask whether the payment increases gradually or depends on crossing a hard threshold. A cliff can make a small difference in results produce a large difference in compensation. Confirm whether a payout rate applies to all qualifying performance or only the amount above the threshold. State the maximum, minimum, rounding convention, and treatment of negative results. Test the formula at several points, including immediately below and above every threshold, rather than checking only the buyer’s optimistic example.
Determine whether each period stands alone or whether later performance can make up an earlier shortfall. A calendar-year test starting soon after closing differs from a full twelve-month measurement period. If the metric is collections, examine the cutoff for services provided near the end: who completes billing, pursues valid appeals, and records later receipts? Ask whether the agreement includes an agreed collection tail or another method for treating that timing. Do not assume it does.
Identify who controls budgets, hiring, site consolidation, payer participation, and billing-system changes after closing. Compare those powers with the assumptions behind the target. The Upbound–Bridge IT agreement cited above includes specific operating and recordkeeping covenants, illustrating that these protections can be expressly negotiated. For your deal, ask counsel what protections are appropriate and enforceable. A conversation about supporting growth is less useful than clear responsibilities, reporting, and remedies that fit the buyer’s actual integration plan.
If payment depends on an earnings measure, work through a sample month showing centralized billing, insurance, management fees, recruiting, and technology migration costs. Ask which charges enter the calculation and whether allocation methods can change. A 2008 Cross Country Healthcare acquisition filing provides a historical example of detailed restrictions on overhead and other earnout expenses. It is a drafting illustration, not evidence of current market practice. Your agreement needs its own cost schedule.
Read what happens if you resign, are terminated, become unable to work, or change roles. Does departure affect already-earned amounts, future eligibility, or both? Also ask what happens if the buyer closes a site, transfers a payer contract, merges the operation into another unit, or sells the company again. Discuss whether acceleration, continued measurement, or another remedy should apply. These are negotiation questions for counsel; continued employment and acquisition consideration should not be treated as interchangeable without analysis.
Identify the entity that owes the money and what financial resources stand behind that obligation. An amount can be earned before it is paid. Ask when funds are due after the calculation is final, whether interest applies to late payment, and whether disputed claims can be deducted or held back. If a guaranty or other protection is proposed, have counsel review its scope. Include these collection risks when comparing the contingent offer with a lower but more certain proposal.
Assume an illustrative agreement pays $2 for each $1 of contract-defined earnings above $1,500,000 during one measurement period, with a $1,000,000 cap. At $1,400,000 of earnings, the payment is zero. At $1,800,000, the $300,000 excess produces a $600,000 payment. At $2,100,000, the formula produces $1,200,000 before the cap, so payment is $1,000,000. These invented thresholds, rates, and amounts are for explanation only. They are not treatment-center benchmarks, recommended terms, or a forecast of what any owner will receive.
Continue the same hypothetical. Suppose the business produces $1,800,000 before a disputed $150,000 integration charge. If that charge is included, measured earnings fall to $1,650,000. The $150,000 excess over the threshold then produces $300,000, rather than $600,000. The allocation dispute changes the earnout by $300,000. Ask whether the contract would include that charge, who supplies the evidence, and how a disagreement is resolved. Repeat the exercise for a delayed billing conversion and an operational change the buyer wants to make.
Coordinate the earnout with the working capital adjustment. A refund, receivable reserve, or preclosing claim can affect more than one calculation. Ask your advisers to trace these overlaps and document the intended treatment so the same economic item does not produce an unintended duplicate reduction.
Create a short review packet that makes the offer testable. Your accountant should be able to recreate the arithmetic, and your lawyer should be able to identify the obligations supporting it. Request:
Record access requires practical detail. For example, the 2026 Brookfield–Oaktree transaction agreement specifies supporting workpapers and review access. That is a non-healthcare illustration. For treatment center data, have privacy counsel define a lawful process; financial verification does not justify unrestricted access to patient records.
An earnout must never create pressure to provide unnecessary care, extend treatment beyond clinical need, or reward improper referrals. HHS OIG’s fraud-and-abuse guidance explains the federal Anti-Kickback Statute’s restrictions on remuneration intended to induce or reward federal healthcare program business. Ask healthcare counsel to evaluate the proposed structure under all applicable federal and state requirements. Preserve qualified clinicians’ independent judgment. If clinically appropriate care or a necessary compliance correction lowers the forecast, revise the economics rather than the care. A financial metric alone does not establish that the arrangement is compliant.
Build a comparison showing the amount payable at closing and the possible later proceeds under zero, partial, and full earnout cases. State assumptions instead of assigning unsupported probabilities. Include timing, payment risk, employment requirements, and potential dispute costs. Ask your tax adviser to model the actual structure: IRS Publication 537 explains that contingent-payment sales can require different calculations from fixed-price installment sales. Do not assume every earnout receives one tax treatment or that all tax follows cash receipt.
If your priority is a clean departure, consider how much ongoing participation the proposal demands. If the offer also includes rollover equity, analyze that continuing investment separately. The earnout is a contractual payment opportunity; rollover carries ownership rights and investment risk. Put the chosen terms into the LOI discussion before exclusivity narrows your alternatives.
Tony Siebel is the Founder and Managing Director of Olympic M&A. His background includes corporate development and physician-practice acquisitions at MDVIP, as well as serving as Vice President and Associate Partner at Stoneridge Partners, including work in its Behavioral Health Division.
Olympic M&A advises founders and healthcare business owners on transactions with private equity groups and strategic acquirers. Learn more about the firm’s behavioral health advisory services and discuss the scope of support appropriate for your business.
Contact Olympic M&A | info@olympicma.com | 502.360.8320